Search - tctmd.com

Displaying 121 - 140 of 185

Sort: Relevancy | Date

News Daily News

Un Estudio OCT Sugiere que ‘Tapar’ la Placa es Más Seguro con BRS que con SMD

November 06, 2014

News Daily News

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

November 06, 2014

News Daily News

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

L.A. McKeown

November 02, 2014

News Daily News

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

L.A. McKeown

November 02, 2014

Presentation

TCT 2014 Top Late Breaking Trials: Coronary Studies

Presenter: Gregg W. Stone

October 21, 2014

Presentation TCT 2014

Absorb III/IV: Angina and Ischemia Hypotheses

Presenter: Mitchell W. Krucoff, John A. Ormiston, Robert-Jan van Geuns, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

Presentation BRS 2014

BRS Capping of Vulnerable Plaque: PROSPECT ABSORB

Presenter: Gregg W. Stone

July 26, 2014

Presentation BRS 2014

Demonstration of Clinical Superiority with a Bioresorbable Vascular Scaffold: The ABSORB III + IV Clinical Trial Program

Presenter: Gregg W. Stone

July 25, 2014

News Daily News

生物吸收支架表现良好，但是血栓形成引担忧

Todd Neale

July 24, 2014

News Daily News

El Andamiaje Bioabsorbible tiene un Buen Rendimiento aunque Preocupa la Trombosis

Todd Neale

July 24, 2014

News Daily News

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

Todd Neale

July 24, 2014

Presentation Fellows 2014

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 12, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Daily News

Los Resultados SLF Varían según el Estado de la Diabetes y la Complejidad de la Lesión

Caitlin E. Cox

March 13, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Daily News

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

January 01, 2014

Advertisement

Un Estudio OCT Sugiere que ‘Tapar’ la Placa es Más Seguro con BRS que con SMD

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

TCT 2014 Top Late Breaking Trials: Coronary Studies

Absorb III/IV: Angina and Ischemia Hypotheses

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

BRS Capping of Vulnerable Plaque: PROSPECT ABSORB

Demonstration of Clinical Superiority with a Bioresorbable Vascular Scaffold: The ABSORB III + IV Clinical Trial Program

生物吸收支架表现良好，但是血栓形成引担忧

El Andamiaje Bioabsorbible tiene un Buen Rendimiento aunque Preocupa la Trombosis

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

Drug-Eluting Stents: Past, Present, and Future

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Los Resultados SLF Varían según el Estado de la Diabetes y la Complejidad de la Lesión

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content